AIMS/HYPOTHESIS: Subclinical left ventricular (LV) dysfunction has been shown by tissue Doppler and strain imaging in diabetic patients in the absence of coronary disease or LV hypertrophy, but the prevalence and aetiology of this finding remain unclear. This study sought to identify the prevalence and the determinants of subclinical diabetic heart disease. METHODS: A group of 219 unselected patients with type 2 diabetes without known cardiac disease underwent resting and stress echocardiography. After exclusion of coronary artery disease or LV hypertrophy, the remaining 120 patients (age 57+/-10 years, 73 male) were studied with tissue Doppler imaging. Peak systolic strain of each wall and systolic (Sm) and diastolic (Em) velocity of each basal segment were measured from the three apical views and averaged for each patient. Significant subclinical LV dysfunction was identified according to Sm and Em normal ranges adjusted by age and sex. Strain and Em were correlated with clinical, therapeutic, echocardiographic and biochemical variables, and significant independent associations were sought using a multiple linear regression model. RESULTS: Significant subclinical LV dysfunction was present in 27% diabetic patients. Myocardial systolic dysfunction by peak strain was independently associated with glycosylated haemoglobin level (p<0.001) and lack of angiotensin-converting enzyme inhibitor treatment (p=0.003). Myocardial diastolic function (Em) was independently predicted by age (p=0.013), hypertension (p=0.001), insulin (p=0.008) and metformin (p=0.01) treatment. CONCLUSIONS/ INTERPRETATION: In patients with diabetes mellitus, subclinical LV dysfunction is common and associated with poor diabetic control, advancing age, hypertension and metformin treatment; ACE inhibitor and insulin therapies appear to be protective.
AIMS/HYPOTHESIS: Subclinical left ventricular (LV) dysfunction has been shown by tissue Doppler and strain imaging in diabeticpatients in the absence of coronary disease or LV hypertrophy, but the prevalence and aetiology of this finding remain unclear. This study sought to identify the prevalence and the determinants of subclinical diabetic heart disease. METHODS: A group of 219 unselected patients with type 2 diabetes without known cardiac disease underwent resting and stress echocardiography. After exclusion of coronary artery disease or LV hypertrophy, the remaining 120 patients (age 57+/-10 years, 73 male) were studied with tissue Doppler imaging. Peak systolic strain of each wall and systolic (Sm) and diastolic (Em) velocity of each basal segment were measured from the three apical views and averaged for each patient. Significant subclinical LV dysfunction was identified according to Sm and Em normal ranges adjusted by age and sex. Strain and Em were correlated with clinical, therapeutic, echocardiographic and biochemical variables, and significant independent associations were sought using a multiple linear regression model. RESULTS: Significant subclinical LV dysfunction was present in 27% diabeticpatients. Myocardial systolic dysfunction by peak strain was independently associated with glycosylated haemoglobin level (p<0.001) and lack of angiotensin-converting enzyme inhibitor treatment (p=0.003). Myocardial diastolic function (Em) was independently predicted by age (p=0.013), hypertension (p=0.001), insulin (p=0.008) and metformin (p=0.01) treatment. CONCLUSIONS/ INTERPRETATION: In patients with diabetes mellitus, subclinical LV dysfunction is common and associated with poor diabetic control, advancing age, hypertension and metformin treatment; ACE inhibitor and insulin therapies appear to be protective.
Authors: L H Kuller; P Velentgas; J Barzilay; N J Beauchamp; D H O'Leary; P J Savage Journal: Arterioscler Thromb Vasc Biol Date: 2000-03 Impact factor: 8.311
Authors: Nikolay P Nikitin; Klaus K A Witte; Simon D R Thackray; Ramesh de Silva; Andrew L Clark; John G F Cleland Journal: J Am Soc Echocardiogr Date: 2003-09 Impact factor: 5.251
Authors: Thomas H Schindler; Alvaro D Facta; John O Prior; Roxana Campisi; Masayuki Inubushi; Michael C Kreissl; Xiao-Li Zhang; James Sayre; Magnus Dahlbom; Heinrich R Schelbert Journal: Eur J Nucl Med Mol Imaging Date: 2006-04-26 Impact factor: 9.236
Authors: Margret Leosdottir; Ronnie Willenheimer; Jonathan Plehn; Rasmus Borgquist; Petri Gudmundsson; Tamara B Harris; Lenore J Launer; Halldora Bjornsdottir; Peter M Nilsson; Vilmundur Gudnason Journal: Am Heart J Date: 2010-03 Impact factor: 4.749
Authors: Charlotte Andersson; Gunnar H Gislason; Peter Weeke; Søren Hoffmann; Peter R Hansen; Christian Torp-Pedersen; Peter Søgaard Journal: Cardiovasc Diabetol Date: 2010-01-18 Impact factor: 9.951
Authors: Omar Asghar; Ahmed Al-Sunni; Kaivan Khavandi; Ali Khavandi; Sarah Withers; Adam Greenstein; Anthony M Heagerty; Rayaz A Malik Journal: Clin Sci (Lond) Date: 2009-05 Impact factor: 6.124